Abstract:We showed the development of a novel pyrrolopyrimidine derivative as an anti‐glioma agent via potent inhibition of EGFR‐TK. The results suggest that the most potent EGFR‐TK inhibitor, compound 4i, significantly inhibited the proliferation of both wild‐type and mutant glioblastoma cells. It also promoted apoptosis of glioblastoma cells by cell cycle arrest at the G2 phase, possibly via attenuating EGFR‐TK. Glioma is an aggressive type of brain malignancy responsible for significant morbidity and mortality. In the current scenario, epidermal growth factor receptor (EGFR) kinases targeted therapy showed significant benefits in glioma patients. Therefore, in the present study, we intend to investigate the anti‐glioma potential of a novel class of pyrazole‐pyrrolopyrimidine derivatives and their mechanism of action. The compounds will be synthesized in a straight‐forward synthetic route in excellent yields and subsequently tested for EGFR kinase inhibition. The compounds showed a diverse range of inhibitory activity against EGFR (IC50 = 3.4–873.2 nM). With an IC50 of 1.5 nM, compound 4i was determined to be the most effective EGFR inhibitor, even superior to the standard erlotinib (IC50 2.3 nM). Among them, the three most potent compounds (4i, 4j, and 4k) were further subjected to the anticancer activity against the panel of various cancer cell lines MCF‐7 (breast cancer), A549 (lung cancer), U87 (glioblastoma cell)‐EGFR‐Wild Type, U87 (mutant glioblastoma cells) EGFR‐mutant cell, MCF‐12A (normal cells). The compound 4i showed the most potent activity against glioblastoma cells as compared to other cancer cells. The effect of compound 4i was also studied on the apoptosis of U87 cells, where it showed induction of apoptosis in a concentration‐dependent manner. It also showed inhibition of the G2/M cell cycle phase of U87 cells. Our study demonstrated the development of novel pyrazole‐pyrrolopyrimidine derivatives as a novel class of anti‐glioma agents.

P129, a pyrazole ring-containing isolongifolanone-derivate: synthesis and investigation of anti-glioma action mechanism

Pyrazole Ring-Containing Isolongifolanone Derivatives As Potential Cdk2 Inhibitors: Evaluation Of Anticancer Activity And Investigation Of Action Mechanism

Inhibition of Human Glioblastoma Multiforme Cells by 10,11-Dehydrocurvularin Through the MMP-2 and PI3K/AKT Signaling Pathways

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of Novel N -(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma

A Novel Dual Pi3k Alpha/Mtor Inhibitor Pi-103 with High Antitumor Activity in Non-Small Cell Lung Cancer Cells

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent

Design, Synthesis and Biological Evaluation of N-alkyl or Aryl Substituted Isoindigo Derivatives As Potential Dual Cyclin-Dependent Kinase 2 (cdk2)/glycogen Synthase Kinase 3β (Gsk-3Β) Phosphorylation Inhibitors.

Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors

Synthesis and Biological Evaluation of Novel Pyrazoline Derivatives Containing Indole Skeleton As Anti-Cancer Agents Targeting Topoisomerase II.

Non-alkylator Anti-Glioblastoma Agents Induced Cell Cycle G2/M Arrest and Apoptosis:Design, in Silico Physicochemical and SAR Studies of 2-Aminoquinoline-3-carboxamides.

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.

Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors

Discovery of Novel Isoquinoline Analogues as Dual Tubulin Polymerization/V-ATPase Inhibitors with Immunogenic Cell Death Induction

Design and discovery of novel pyrazole‐pyrrolopyrimidine derivatives as anti‐glioma agents via promoting apoptosis, inhibiting cell cycle and EGFR‐TK

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

The Nitro Group Reshapes the Effects of Pyrido[3,4-g]quinazoline Derivatives on DYRK/CLK Activity and RNA Splicing in Glioblastoma Cells

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.